Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 February 2000Website:
http://www.agenusbio.comNext earnings report:
14 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 23:39:01 GMTDividend
Analysts recommendations
Institutional Ownership
AGEN Latest News
Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Agenus (AGEN) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $2.10. This compares to loss of $3.20 per share a year ago.
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110801&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110719&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024.
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110658&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110613&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , Nov. 4, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110633&wire=1 or contact Joseph E. Levi, Esq.
What type of business is Agenus?
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
What sector is Agenus in?
Agenus is in the Healthcare sector
What industry is Agenus in?
Agenus is in the Biotechnology industry
What country is Agenus from?
Agenus is headquartered in United States
When did Agenus go public?
Agenus initial public offering (IPO) was on 08 February 2000
What is Agenus website?
https://www.agenusbio.com
Is Agenus in the S&P 500?
No, Agenus is not included in the S&P 500 index
Is Agenus in the NASDAQ 100?
No, Agenus is not included in the NASDAQ 100 index
Is Agenus in the Dow Jones?
No, Agenus is not included in the Dow Jones index
When was Agenus the previous earnings report?
No data
When does Agenus earnings report?
The next expected earnings date for Agenus is 14 March 2025